Session » (2370–2386) Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 2370

C5 as a Genetic Marker for Discriminating Between IgA Vasculitis and IgA Nephropathy?

Abstract Number: 2371

Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis

Abstract Number: 2372

Soluble Triggering Receptor Expressed on Myeloid Cell-1 Reflects the Cross-sectional Activity of Microscopic Polyangiitis and Granulomatosis with Polyangiitis

Abstract Number: 2373

SIRPα Expression in Systemic Vasculitis

Abstract Number: 2374

Torque Teno Virus as a Potential Biomarker for Assessment of Immunocompetence in Patients with ANCA-associated Vasculitis

Abstract Number: 2375

Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7

Abstract Number: 2376

Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis

Abstract Number: 2377

The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis

Abstract Number: 2378

Longitudinal Trajectories of Renal Function in ANCA-Associated Vasculitis: Findings from the Expanded Mass General Brigham Cohort

Abstract Number: 2379

A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy

Abstract Number: 2380

Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data

Abstract Number: 2381

ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain

Abstract Number: 2382

Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis

Abstract Number: 2383

Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Dual Positive Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody: A Single Center Experience

Abstract Number: 2384

Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group

Abstract Number: 2385

Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis

Abstract Number: 2386

Impact of ANCA Specificity on Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.